Probiotics for the treatment of Clostridium difficile associated disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The purpose of this review paper is to update the current and potential future role of probiotics for Clostridium difficile-associated disease (CDAD). Included in this review, is an update on the testing of newer probiotics (e.g., Bacillus coagulans GBI-30, 6086) in animal models of CDAD. There is a focus on the modulation of signal transduction pathways (i.e., transcription factors like cAMP response element-binding, activator protein 1, and nuclear factor kappa B), as well as the inhibition of certain kinases (e.g., p38 mitogen activated protein kinases) by probiotics. Inhibition of signal transduction by probiotics, such as Saccharomyces boulardii, result in multiple effects on intestinal fluid secretion, neutrophil influx into the colon, inflammation, and colonocyte apoptosis that may positively impact CDAD. Recent clinical approaches with probiotics, for the prevention of primary and recurrent CDAD, are also summarized in this review paper. Future directions for the treatment of CDAD by probiotics are also mentioned in this review. In particular, the use of multi-strain probiotic formulations such as Ecologic(®) AAD and VSL #3(®) may represent a rationale pharmacological approach, particularly as adjunctive therapies for CDAD. Understanding the mechanistic basis of CDAD, and how probiotics interfere at ceratin steps in the pathogenic process, may also present the opportunity to design other multi-strain probiotics that could have a future impact on CDAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672
Mechanisms of action of probiotics: Recent advances
Ng, S. C., Hart, A. L., Kamm, M. A., Stagg, A. J., & Knight, S. C. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20602 · Cited by 596
A mouse model of clostridium difficile-associated disease
Chen, X., Katchar, K., Goldsmith, J. D., Nanthakumar, N., Cheknis, A., Gerding, D. N., & Kelly, C. P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.002 · Cited by 510
Johnston, B. C., Ma, S. S. Y., Goldenberg, J. Z., Thorlund, K., Vandvik, P. O., Loeb, M., & Guyatt, G. H. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-12-201212180-00563 · Cited by 367
Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases1
Chapman, T. M., Plosker, G. L., & Figgitt, D. P. (2007) · BioDrugs · doi:10.2165/00063030-200721010-00007 · Cited by 48
Cited by
Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature
Fijan, S. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph110504745 · Cited by 1,059
“boulardii together with standard antibiotics [62].”
BackgroundBeneficial modulation of the gut microbiota
Walsh, C. J., Guinane, C. M., O'Toole, P. W., & Cotter, P. D. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.035 · Cited by 274
Aroutcheva, A., Auclair, J., Frappier, M., Millette, M., Lolans, K., de Montigny, D., Carrière, S., Sokalski, S., Trick, W. E., & Weinstein, R. A. (2016) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-016-9209-y · Cited by 25
Evaluation of the Role of Probiotics As a New Strategy to Eliminate Microbial Toxins: A Review
Ghadaksaz, A., Nodoushan, S. M., Sedighian, H., Behzadi, E., & Fooladi, A. A. I. (2022) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-021-09893-2 · Cited by 20
Metadata
- Authors
- Fitzpatrick, L. R.
- Venue
- World Journal of Gastrointestinal Pathophysiology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2013
- Volume
- 4
- Issue
- 3
- Pages
- 47
- ISSN
- 2150-5330 (ISSN-L)
- OpenAlex
- W1992643331
- Cited by
- 34
- References
- 5
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.